Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled trial of RBD5044 in mixed dyslipidemia
2023-510369-92-00Phase 2Authorised
- Sponsor
- Ribocure Pharmaceuticals AB
- Start
- Oct 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in combined dyslipidaemia comparing RBD5044 with Placebo (2 arms). Primary endpoint: Percent change from baseline in triglyceride levels at week 16. Planned start Oct 2024; status: authorised.
02
Drugs
rbd5044
03
Conditions
combined dyslipidaemia
Beyond the preview
Go deeper on 2023-510369-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510369-92-00.